RESULTS
cancer, heart failure, T2DM
KIDNEY DISEASE, CANCER, LIVER DISEASE, HEART FAILURE, CEREBROVASCULAR DISEASE
A total of 399 784 patients with T2DM were enrolled in this study. During a median follow‐up of 6.93 years (IQR 5.64–8.31 years), 68 318 patients died, with an all‐cause mortality of 2.54 per 100 person‐years. The median age was 63 years (IQR 56–72 years), and 51.11% were male. Table Baseline characteristics of the study populationAbbreviations: HbA1c, glycosylated hemoglobin; HDL‐C, high‐density lipoprotein cholesterol; IQR, interquartile range; LDL‐C, low‐density lipoprotein cholesterol; SMD, standardized mean difference.Median of the values of the 10 imputed datasets.Variable selection was performed in each of the 10 imputed training datasets. Predictors included in the final model were age, sex, heart failure, cerebrovascular disease, moderate or severe kidney disease, moderate or severe liver disease, cancer, insulin use, HbA1c, and HDL‐C. Table Results of univariate and multivariate Cox proportional hazards models for all‐cause mortality in the training setAbbreviations: CI, confidence interval; HbA1c, glycosylated hemoglobin; HDL‐C, high‐density lipoprotein cholesterol; HR, hazard ratio; SExample: 65 years old; male; history of heart failure, cerebrovascular disease, moderate or severe kidney disease, moderate or severe liver disease, and cancer; use of insulin; HbA1c level = 12.00%, HDL‐C level = 1.00 mmol/L.5‐year all‐cause mortality risk ≈ 86.94%Table C‐index of the imputed validation datasets and complete datasetAbbreviation: CI, confidence interval.Calibration curves of the 5‐year all‐cause mortality risk prediction model in the imputed validation datasets